Objective: Determine reliability and basic psychometric properties of a composite cognitive endpoint, MS-COG, for monitoring change in cognitive function in MS drug trials. Background: 50% of MS patients have cognitive impairment that impacts ability to work and quality of life. We selected neuropsychological tests based on sensitivity to MS cognitive impairment, availability of alternate forms, cross-cultural utility, and feasibility for multicenter trials, and assessed the reliability and validity of a composite endpoint, MS-COG. Design/methods: Administered SRT, BVMT-R, PASAT, and SDMT to 60 MS patients at 4 US centers twice over 45 days, along with symptom inventories by patients and informants. Results: The MS-COG had test-retest reliability of 0.91. Processing Speed and Memory indices had reliabilities of 0.89 and 0.86, with modest practice effects. Reliability was high for the RR MS and SP MS subgroups as well, with correlations of .90 and .93, respectively for MS-COG. Overall, 42% of subjects obtained MS-COG scores in the impaired range, with SP MS subjects performing 0.8 SD below RR MS subjects. Impairment correlated well (r = 0.37 to 0.40) with informant reports but was inconsistent with patient report, with the least reliable assessments by those with greater symptom severity. Conclusions: The MS-COG is a reliable, repeatable measure of MS cognitive functioning that is sensitive to cognitive impairment in SP MS and RR MS patients and feasible for multicenter clinical trials. Further development is warranted.
Introduction
Cognitive Impairment Associated with Multiple Sclerosis (CIAMS) [1] is common, with frequencies ranging from 40 to 75% reported in clinical samples [2] [3] [4] [5] and meta-analyses [6] [7] [8] [9] [10] , with estimates varying according to the definition of cognitive impairment. Processing Speed and Learning/Memory are the domains identified as most likely to be impaired in individual MS subjects with frequency rates estimated at approximately 52% and 54%, respectively, [11, 12] with impairment in each domain manifesting at differing levels of severity within individual patients [13] . These cognitive impairments are relatively independent of MS symptoms that cause motor impairment [6, 14] and comprise a significant contributing factor to overall disability and lessened quality of life [15] . A pharmaceutical therapy that improves cognitive functioning in MS patients would therefore be of considerable value in the overall management of MS. However, in order to assess the effectiveness of pharmaceutical interventions, reliable and valid indices of meaningful cognitive change that are feasible for multicenter clinical trials are required.
The present study sought to determine the reliability of a composite endpoint (MS-COG) for use in determining efficacy of disease modifying pharmaceutical agents in the improvement of cognitive functioning in MS patients. An a priori composite endpoint merits investigation as similar composite endpoints for other disease entities that have been required by FDA in past trials [16] [17] [18] . In addition, a composite endpoint offers a number of potential general advantages, such as lower error rates, improved reliability, and greater simplicity in summarizing treatment effects and relating clinical meaningfulness of the observed changes [16] [17] [18] [19] . There are, of course, disadvantages in collapsing multiple domains into a single endpoint, including potentially decreased sensitivity in comparison to a single endpoint and greater difficulty in interpretation of any change identified. In regard to the former, when a pharmaceutical agent aims to improve cognitive functioning generally, focus on change in an individual domain may potentially disproportionally represent improvement in a given subject if such gains are not present in other domains. We therefore recommended combining multiple domains in a single endpoint. In regard to the latter, clinical interpretation of the composite endpoints will still require scrutiny of the underlying factors.
Although there have been a number of MS studies examining potential improvement due to the effects of a pharmaceutical agent on individual tests of cognitive functioning over the course of a trial [20] [21] [22] , little research has been published examining the effects of such an agent on general neuropsychological test performance in MS. An earlier investigation by Fischer et al. [23] examined the effects of intramuscular interferon beta-1a (Avonex®) in MS patients using a comprehensive neuropsychological test battery administered over a 2 year time span in a subset of English speaking subjects from the Phase 3 registrational clinical trial (MSCRG study). Tests measuring Learning, Memory, and Processing Speed were group together post hoc as being the most frequently impaired domains. A significant improvement of approximately 0.5 standard deviations was identified for Avonex over placebo. Subsequent efforts by Rao [24] and Benedict et al. [25] demonstrated that briefer assessments than used by Fischer et al. might be useful for identifying cognitive impairment in MS, but their operational feasibility has limited their use in drug trials.
The current project began when Biogen Idec recruited a panel of advisors with extensive experience in research on cognitive impairment in MS clinical pharmaceutical research populations (authors DE, RB, FF, JW, and JD). In recommending tests for the current research, the advisory panel considered not only the sensitivity of the proposed component tests to MS impairment, but also test-retest reliability, the availability of multiple alternate forms for longitudinal studies, suitability for administration by newly trained clinical staff, and the feasibility for use in cross-cultural and linguistic settings. In considering these factors, the expert panel chose the Paced Auditory Serial Addition Test (PASAT) [24, 26] , Selective Reminding Test (SRT) [27] , Symbol Digit Modalities Test (SDMT) [24, 28] , and Brief Visuospatial Memory Test -Revised (BVMT-R) [29] to cover the two cognitive domains most affected in MS, information processing (PASAT and SDMT) and Learning and Memory (SRT and BVMT-R). Notably, these tests were identified by Strober et al. [30] as having optimal sensitivity to detect impairment in the MS population, with effect sizes ranging from d = 0.7 to d = 1.1, which was not the case for tests of other domains included in previous MS Cognitive Batteries such as executive functions, language, and visuospatial judgment [31] .
The current study sought to establish the basis for combining the neuropsychological measures selected by the expert panel into a single endpoint, the MS-COG, for use in pharmaceutical research, and determine basic psychometric properties related to reliability. An investigation of the relationship of the endpoint to the observations of the patient and their designated caregiver on real world cognitive function was also investigated.
Methods

Participants
Subjects were recruited from existing patient lists from four MS centers in the United States, each recruiting 15 patients with documented history of Relapsing-Remitting (RR) or Secondary Progressive (SP) MS. Participants who agreed to enroll were paid $60. Participants were included regardless of MS severity, presence of cognitive impairment, or duration of illness so as to be representative of MS clinic patients generally. Exclusion criteria included physical or sensory impairment that might preclude completion of cognitive test protocols, untreated major depressive and/or untreated anxiety disorder of sufficient severity to potentially to impact cognitive skills, history of severe psychiatric illness such as bipolar disorder or schizophrenia, or severe traumatic brain injury or other medical illnesses that would preclude valid completion of the assessments. One subject was excluded after enrolment because of the onset of clinically significant symptoms of depression following Study Day 1 and which were of sufficient severity such that the subject was unable to travel to the research site. All other patients were neurologically and psychiatrically stable for the duration of the study.
Demographic characteristics of the sample identified the group as typical of clinical MS populations [12] as well as of populations recruited for pharmaceutical studies [22] . The group was comprised of 43 women (72%) and 16 men (28%) recruited from lists of patients diagnosed with MS according to McDonald criteria in 4 U.S. clinics, with an average age of 47.9 (SD = 7.9; range = 26-61). A majority (77%) were receiving disease modifying therapy. Average time since diagnosis was 13.2 years (SD = 8.5; range = 1-33). Similar to reported studies of other clinical MS populations, the majority (87%) were Caucasian, with 5% identifying as African-American, 5% as Hispanic, and 3% as other; only 2% were not high school graduates, with 27% having a high school degree or GED, 18% an Associate Degree, 28% a Bachelors Degree, 21% a Masters Degree and 5% an advanced degree; the median Expanded Disability Status Scale (EDSS) [32] was 2.5 and the mode was 2; approximately 77% of participants had a diagnosis of RR MS and 23% one of SP MS; [12, 24, 33] . As might be expected, the group diagnosed with SP MS was significantly older than that of patients with RR MS (55.1 ± 5.6 years vs. 47.9 ± 9.2 years) and had significantly higher EDSS ratings (4.2 ± 1.8 vs. 2.2 ± 1.5). The groups did not differ in regard to education or ethnicity.
Procedures
Participants were assessed at two time points, approximately 45 days apart. Each participant completed the SDMT Oral Version, PASAT, BVMT-R, and SRT on each occasion. A 45 day retest interval was chosen based on clinical observations that this was sufficient for identification of change on measures of memory in a prior MS study [22, 34] . Order of test administration was as follows: SRT and BVMT-R Learning Trials, SDMT, PASAT 3-and 2-second trials, SRT Delayed Recall, BVMT-R Delayed Recall. Total time for administration was approximately 30 min. Equivalent alternate forms were used to minimize form-specific practice effects. Self-report forms-the Multiple Sclerosis Quality of Life-54 (MSQOL-54: cite), the Memory Functioning Questionnaire (MFQ) [35] and the Multiple Sclerosis Neuropsychological Questionnaire-Patient (MSNQ-P) [36, 37] were administered prior to the neuropsychological tests in order to limit the degree to which a subject based her/his opinion on test performances. The Multiple Sclerosis Neuropsychological Questionnaire-Informant (MSNQ-I) [36, 37] as completed at the convenience of the caregiver without knowledge of actual test performance and returned to the investigator.
MS-COG test instruments
Symbol Digit Modalities Test (SDMT)
In this measure of Processing Speed and Working Visual Memory, the subject is given 90 s to pair specific numbers with given geometric figures based on a reference key using an oral response, to limit problems due to dexterity in MS patients [24] . At Study Day 1 the original, WPS-published form was administered [28] and at Visit 2 Rao's Form 2 [38] was administered.
Paced Auditory Serial Addition Test (PASAT)
First developed by Gronwall to assess patients recovering from concussion [39] , the PASAT requires patients to monitor a series of 61 audiotaped digits while adding each consecutive digit to the one immediately preceding it. The numbers of intervals and presentation rates were subsequently modified by Rao [38] calling for two trials, with inter-stimulus intervals of 3 and 2 s, respectively. Rao's Forms A and B were administered at Study Days 1 and 2, respectively.
Selective Reminding Test
The history of this test begins with the work of Buschke and Fuld who conducted research in the area of anterograde amnesia [27] . After the examiner reads a list of 12 target words on an initial learning trial, the test-taker is asked to try to repeat the entire list. On 5 subsequent learning trials, the SRT requires the experimenter to repeat only target words not recalled by the subject on the previous trial, and test-taker is asked to repeat the entire list. A Delayed Recall trial is included. Hannay and Levin's word lists for adults, Forms 1 and 3, were selected for this study based on available research demonstrating equivalence in difficulty [40] .
Brief Visuospatial Memory Test -Revised
The Brief Visuospatial Memory Test -Revised (BVMT-R) is based on an initial effort to develop equivalent alternate form Visual Memory tests [41, 42] . In the revised version [29, 43] , the BVMT-R includes three 10-s exposures to the stimulus. After each exposure, the subject is asked to reproduce the matrix with using a pencil on a blank sheet of paper. Further, there is extensive research showing that all 6 forms of the test are of equivalent difficulty. Variables of interest in the current study were the Total Learning and Delayed Recall scores. In the current study, Forms 1 and 4 were utilized based on the recommendation of the test author (RB) and his knowledge of the research on this measure.
Memory Functioning Questionnaire
The Memory Functioning Questionnaire [44] was designed to examine self-reported memory complaints. It consists of 64 items addressing memory difficulty and frequency of forgetting, presented in 7 sections, each rated on a 7-point scale.
MS Neuropsychological Questionnaire
The MSNQ [36] is a 15-item report schedule with versions developed both for patient-and informant-reports of cognitive and neuropsychiatric symptoms commonly observed in the MS population.
MS Quality of Life-54
The MSQOL-54 was developed by combining the most widely utilized generic measure of quality of life in the world, the SF-36, with additional items specific to MS.
Data analyses
Analyses were completed using SPSS software. All subjects who completed both visits were included in all data analyses. Of these subjects, data for the PASAT 2″ trial was not available for one participant not completing the procedure at the initial visit after becoming overly frustrated. All raw scores were converted into demographically adjusted z scores using peer-reviewed control data from subjects [30] similar in age, gender and education to the current study group, recruited through newspaper advertisements for a different MS study [30] . For the purposes of the current study in which correlations among tests were of interest, it was decided that using control data from a group administered all of the same tests was preferable to use of disparate normative databases, despite the limitations of using this relatively small comparison group. Indeed, future research plans include compilation of a larger comparison group of healthy subjects. Z scores were used for all analyses. Reliability was investigated using Pearson r correlations and intraclass correlations. Qualitative characterization of reliabilities is discussed below in keeping with Slick [45] . A priori assumptions based on existing literature [12, 46] that PASAT and SDMT could be combined into a Processing Speed factor and that SRT and BVMT-R could be combined into a Learning and Memory Factor were examined using loadings on factor analysis as detailed below. The factors and MS-COG per se were constructed according to clinical usage as detailed below. An a priori cutoff of .70 was established as indicative of minimally acceptable reliability [47] . Exploratory analyses using Pearson r correlations were conducted to examine the associations among the composite endpoint and the self-and informant-report scales.
Results
The population was similar in demographic characteristics to the normative control data [30] used to generate the standard scores, with the respective groups comprised of 72 vs. 84% women with mean age of 47.9 vs. 45.2 years and mean education of 15 years for each group. Subjects were re-tested 28 to 58 days after the initial assessment with a mean interval of 42.7 ± 6.8 days. The individual neuropsychological measures each revealed sensitivity to cognitive impairment in this clinical sample. Standardized summary scores for cognitive indices identified as clinically sensitive by Strober et al. [30] were computed based on that researcher's normative control data which included all the measures of interest. Average performance across subtests was well below the control z score mean of 0 and ranged from − 0.62 to − 1.7. Prevalence of impairment as defined by a score of −1.5 below the control mean or greater ranged from 26% to 54%. Test-retest reliabilities for the individual measures ranged from .63 to .89 with stronger correlations associated with speeded measures in comparison to those of Learning and Memory ( Table 1) .
The standardized summary scores were entered into a factor analysis. Eigenvalues of 4.43 and 1.04 identified two factors accounting for a total of 78% of the variance. All combinations of estimation method (principal axis factoring, maximum likelihood), rotation procedure (orthogonal vs. oblique), and extraction criteria (all factors with eigenvalues N1 vs. only the first two factors) were explored in order to explore the stability of the factors analysis. As illustrated in Table 2 , varimax rotation with Kaiser normalization identified Factor 1 as comprised of loadings of SRT Total Learning and Delayed Recall, BVMT-R Total Learning and Recall, and SDMT with loadings ranging from 0.59 to 0.85. Factor 2 was comprised of SDMT, PASAT 3″ and PASAT 2″ with loadings ranging from 0.57 to 0.95. These factors were labeled Learning and Memory (LM) Factor and Information Processing Speed (IPS) Factor, accordingly.
Construction of the LM composite was accomplished by averaging the standard scores for the 4 component indices, thus giving equal weightings both to Verbal and Visual Memory as well as both to Learning and Delayed Recall scores. This plan was in keeping with each indices' roughly equivalent sensitivity to cognitive impairment in MS patients as detailed by Strober et al. [30] . For the IPS composite, the two PASAT total scores were averaged and then combined with the SDMT, so as to give equal weightings to these different paradigms as well as to reflect Strober et al.'s finding that the SDMT has relatively greater sensitivity to cognitive impairment. The MS-COG was constructed by averaging the LM and IPS composites with equal weighting. This methodology is diagramed in Fig. 1 .
The sensitivity of the LM and IPS composites and MS-COG to impairment was evident in mean scores ranging from z = − 1.14 to z = − 1.19, with the frequency of impairment being comparable to the numerous studies discussed above (Table 3) . Inspection of impairment within vs. across domain indicated that although a total of 54% of the sample was impaired in either IPS or LM, 42% was impaired in both IPS and LM. Notably, the participants impaired in both domains were the same as those identified as impaired by MS-COG. MS-COG, therefore, appeared to have a considerable advantage in identifying participants with a cognitive impairment syndrome in comparison to individual domains. (See Table 2 .)
Reliability of the factor scores and the MS-COG were all considered high with Pearson r and intraclass correlations ranging from .86 to .91 as reported in Table 4 .
Psychometric characteristics of the MS-COG score are reported in Table 5 . As illustrated, the MS-COG showed good sensitivity to impairment as indicated by the mean z score of −1.1 at Visit 1 and was normally distributed, without significant skewness or kurtosis. A practice effect of 0.35 SD ((32% improvement) was evident at Visit 2, although the high reliability demonstrated by the MS-COG indicates that this is not an obstacle to detecting change in cognitive functioning in a longitudinal clinical trial, particularly as there was no evidence of a ceiling effect. Moreover, this retest effect is consistent with similar effects previously reported for these measures [48] .
We calculated standard errors of difference and retest effects for MS-COG and the factor scores to facilitate clinical decision making. These, along with cutoff scores for identifying decline with 80% and 90% confidence are provided in Table 6 . Clinicians would calculate scores as follows: (score at time 2 − (score 1 + retest effect)) / S diff = z. Any z score below − .83 and − 1.26 would be indicative of decline with 80% and 90% confidence, respectively.
To examine the ability of the MS-COG to detect cognitive impairment in MS, severity and frequency of impairment were compared across the Relapsing-Remitting and Secondary Progressive MS subgroups. As would be expected, those participants with Secondary Progressive MS have cognitive impairment of greater severity and were more frequently impaired on both composite domains and on the MS-COG as shown in Table 7 .
Reliability scores according to MS subtype were all high, with Secondary Progressive participants demonstrating marginally greater reliabilities generally as shown in Table 8 .
Pearson r correlations were performed to explore the associations between objective performance on standardized tests of cognitive function (MS-COG) and the self-and informant reported symptoms of cognitive impairment. None of the correlations were strong ( Table 9 ). The hypothesized directions of the MFQ and MSQOL instruments were in the positive direction and that of the MSNQ in the negative direction. The strength and directionality of the associations differed according to MS type, with stronger correlations for reports of RR MS patients than of SP MS patients. Informant reports were more consistent regardless of MS type. Table 9 contains the findings for these subgroups.
Discussion
The current study sought to establish the reliability, and basic psychometric properties of a proposed composite cognitive endpoint (MS-COG) recommended by an expert advisory board for use in research on pharmaceutical interventions to treat CIAMS [1] . MS-COG demonstrated high test-retest reliability of 0.91, which was better than or similar to reports for the component subtests. MS-COG endpoint also demonstrated a normal distribution with no evidence of significant skewness or kurtosis and a standard deviation close to that of a non-impaired population (z = 1.3 for Visit 1; z = 1.1 for Visit 2) which is an important feature for estimating sample sizes for large pharmaceutical trials. Similarly, the standard error of the mean of the MS-COG was small compared to the standard deviation, indicating good potential for accuracy in assessment of each patient.
The psychometric methodology for establishing the IPS and LM composites received preliminary support. Even in this small sample, factor analysis identified two and only two factors which, upon inspection, were comprised of the proposed component subtests in the respective cognitive domains. Within each cognitive domain, the SDMT showed somewhat greater sensitivity than PASAT and the BVMT-R showed somewhat greater sensitivity than SRT. As these observations have been reported in previous studies our confidence was increased that the data collected in the current study was representative of a typical MS clinical sample.
The MS-COG identified 42% of MS patients from 4 US Clinics as having clinically significant cognitive impairment as indicated by a score lower than 5% the comparison group of healthy participant, which is similar to prevalence reported in clinical samples using other assessment methodologies [2] [3] [4] [5] . Further, the IPS and LM composites revealed sensitivities of 40% and 39%, respectively, which are similar to previously reported estimates [11, 12] . Moreover, the frequency of impairment identified by the MS-COG was maintained or increased modestly relative to the LM and IPS composites, indicating that in this battery multidimensional assessment is likely preferable to individual domains for a pharmaceutical trial in which change in generalized cognitive ability is of interest. However, it was clear that if a single domain of impairment were of interest, individual measures such as the SDMT and the BVMT-R would be expected to demonstrate greater sensitivity within their respective domains in comparison to the domain-specific IPS and LM composites. In this light, it is noted that findings of impairment in multiple domains are preferable to single domains if the target of a pharmaceutical intervention is a general cognitive impairment syndrome and not a specific cognitive function. Further, the MS-COG revealed greater frequency of impairment in patients with SP MS vs. RR MS, in keeping with the greater disease severity associated with the former population as documented in numerous research studies [12, 30, 49] .
In light of these strong psychometric properties, we believe that choosing to use the MS-COG in a drug development clinical trial is preferable to methodologies used in past drug studies. The MS-COG also is preferable to the large battery of tests administered by Fischer et al. [23] in English speaking subjects from the Avonex® Phase 3 trial in regard to practicality, and also in regard to availability of alternate forms and validation of component subtests. Further, the MS-COG has psychometric support for the combination of component subtests which was not the case in the Fischer et al., as that research which was guided by clinical judgment, not a priori psychometric research. We also believe that, given further research support and the specific nature of the research question being investigated, the use of the MS-COG might be preferred than the use of current clinical batteries such as the MACFIMS [50] and BRB [51] . That is, while the MACFIMS would be expected to serve as a more robust comprehensive assessment in clinical settings for characterization of neuropsychological status and for guiding treatment and intervention as it provides assessment of 5 rather than 2 domains, it is far lengthier-approximately 90 min vs. 30 min for MS-COG-and has only one alternate form. Indeed, the limitation in available alternate forms is especially salient in memory assessment, indicating that the SRT with 3 alternate forms is greatly preferred to the CVLT for a pharmaceutical trial with more than two assessments. In this light, it is noted that 3 of the 4 tests included in the MS-COG are included in the MACFIMS, identifying the MS-COG as an alternative potentially more suitable for international multi-center pharmaceutical trials in MS due to its relative brevity, repeatability, and its status as a single outcome. Similarly, the MS-COG shares 3 of 4 measures with BRB, although the latter was never developed for use as a single factor outcome. In further support of the acceptability of the subtests comprising the Composite is the selection of some of its components by both BICAMS and the NINDS CDE Task Force [31] . Finally, the subtest components of the MS-COG are easily administered by trained study personnel and not just by neuropsychologists, facilitating feasibility in large international clinical trials. For example, in the current study, test administrators included trained and supervised psychology graduate students and nurses as well as neuropsychologists.
The poor correlation between patient-and informant-reported neuropsychological symptoms and objective performance on the MS-COG was not unexpected as previous researchers have made similar observations [36] . Still, the current study was remarkable for two observations. First, RR MS subjects were clearly better able to perceive their neuropsychological symptoms, as their self-appraisals were moderately correlated with their overall performance, whereas self-appraisals of SP MS subjects consistently lacked meaningful association with their own 0.93 Table 9 Correlations between the MS-COG and symptom reports by MS type. test performances. This is consistent with the observation that selfassessment and insight into symptoms worsens with the severity of cognitive impairment. Second, as has been noted previously, informants can provide useful information regarding MS cognitive problems [36] . Particularly in regard to future studies of cognitively impaired SP MS patients, the current MFQ, MSQOL, and MSNQ findings can be interpreted as strongly supportive of the preferential use of informant reports vs. patient reports. These observations may be relevant and important in guiding future research as patient-and/or informant-reported outcomes are typically areas of interest to regulatory authorities.
In conclusion, based on the present results, we believe that the MS-COG has a reasonably clear psychometric basis, sensitivity similar to a larger and broader battery of tests, a normal distribution of scores, and high test-retest reliability. We note, however, that these statements are limited by the possibility that the results were distorted by the use of demographic adjustments to scores from a single control group vs. a normative database and may be limited in generalizability if MS patients differ significantly in regard to demographics. However, we believe that making such demographic adjustments based on a single normative source is preferable to use of multiple normative databases so long as the two groups are relatively similar, which was the case presently. We also note that the current retest effect may not be representative as we did not counterbalance tests. We expect to investigate this possibility as well as the implications for this in future research efforts. We further note that future studies will be required to establish reliabilities for multiple time points and longer test-retest intervals. The reliability and sensitivity of the MS-COG endpoint may be affected by such parameters. The composite endpoint is comprised of subtests with available alternate forms and limited though supportive evidence of cross-cultural utility, making it feasible for international trials [17, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . We believe that it is reasonable to proceed with proof-ofconcept-type trials for pharmaceutical interventions hypothesizing cognitive benefit using the MS-COG. However, it will be important for such proof-of-concept studies to demonstrate further cross-cultural utility and to clarify the clinical meaningfulness of any observed changes as the current study did not employ any such pharmaceutical intervention.
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